FDA Grants Interchangeability Designation to Celltrion's Denosumab Biosimilars, Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo)

Oct 31, 2025 - 08:00
 0  1
INCHEON, South Korea, Oct. 30, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) as interchangeable biosimilars to the...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0